Patient demographic and background characteristics
| Parameter | |
| Age (years) | 64.6±9.6 (n=999) |
| Male gender (%) | 608 (60.9) |
| BMI (kg/m2) | 24.6±3.9 (n=999) |
| Estimated duration of diabetes (years) | 12.9±8.5 (n=999) |
| Systolic blood pressure (mm Hg) | 131.2±14.8 (n=999) |
| Diastolic blood pressure (mm Hg) | 75.5±11.0 (n=999) |
| HbA1c (%) | 7.1±0.8 (n=999) |
| HbA1c (mmol/mol) | 53.7±8.8 (n=999) |
| Total cholesterol (mmol/L) | 4.81±0.82 (n=964) |
| LDL cholesterol (mmol/L) | 2.67±0.69 (n=990) |
| HDL cholesterol (mmol/L) | 1.56±0.41 (n=998) |
| Triglycerides (mmol/L) | 1.4±0.9(n=999) |
| Uric acid (μmol/L) | 307.4±73.0 (n=994) |
| Estimated glomerular filtration rate (mL/min/1.73 m2) | 73.4±20.6 (n=999) |
| Use of oral glucose-lowering agents (%) | 894 (89.5) |
| Metformin (%) | 543 (54.4) |
| Sulfonylureas (%) | 127 (12.7) |
| Glinides (%) | 68 (6.8) |
| Dipeptidyl peptidase-4 inhibitors (%) | 577 (57.8) |
| Sodium-glucose cotransporter-2 inhibitors (%) | 231 (23.1) |
| Thiazolidinediones (%) | 143 (14.3) |
| α-glucosidase inhibitors (%) | 172 (17.2) |
| Glucagon-like peptide-1 antagonists (%) | 74 (7.4) |
| Insulin (%) | 158 (15.8) |
| Use of antihypertensive drugs | 483 (48.3) |
| ACE inhibitors (%) | 28 (2.8) |
| Angiotensin II receptor blockers (%) | 390 (39.0) |
| Calcium channel blockers (%) | 273 (27.3) |
| Diuretic drugs (%) | 57 (5.7) |
| α-adrenergic receptor antagonists (%) | 19 (1.9) |
| β-adrenergic receptor antagonists (%) | 33 (3.3) |
| Use of lipid-lowering agents (%) | 595 (59.7) |
| Statins (%) | 508 (51.0) |
| Ezetimibe (%) | 107 (10.7) |
| Fibrates (%) | 41 (4.1) |
| Use of antithrombotic agents (%) | 64 (6.4) |
| Antiplatelet agents (%) | 50 (5.0) |
| Anticoagulants (%) | 15 (1.5) |
| FLP-CGM-derived metrics | |
| Mean glucose (mmol/L) | 7.80±1.79 (n=999) |
| SD (mmol/L) | 2.04±0.63 (n=999) |
| CV (%) | 26.2±5.79 (n=999) |
| MAGE (mmol/L) | 5.46±2.00 (n=999) |
| TIR3.9–10 mmol/L (%) | 78.9±18.6 (n=999) |
| TAR>10 mmol/L (%) | 19.0±19.2 (n=999) |
| TAR>13.9 mmol/L (%) | 3.85±9.31 (n=999) |
| TBR<3.9 mmol/L (%) | 2.16±4.71 (n=999) |
| TBR<3.0 mmol/L (%) | 0.33±1.53 (n=999) |
| LBGI | 1.56±1.67 (n=999) |
| HBGI | 5.58±4.64 (n=999) |
| MODD (mmol/L) | 1.73±0.64 (n=999) |
| IQR (mmol/L) | 2.14±0.81 (n=999) |
Data are mean±SD or number of patients (%).
BMI, body mass index; CV, coefficient of variation; FLP-CGM, FreeStyle Libre Pro continuous glucose monitoring device; HbA1c, hemoglobin A1c; HBGI, high blood glucose index; HDL, high-density lipoprotein; LBGI, low blood glucose index; LDL, low-density lipoprotein; MAGE, mean amplitude of glycemic excursions; MODD, mean of daily differences; TAR, time above range; TBR, time below range; TIR, time in range.